Zobrazeno 1 - 10
of 38
pro vyhledávání: '"ChangWon C Lee"'
Autor:
Nora A Moskowitz, Alexandre B Roland, Eva K Fischer, Ndimbintsoa Ranaivorazo, Charles Vidoudez, Marianne T Aguilar, Sophia M Caldera, Jacqueline Chea, Miruna G Cristus, Jett P Crowdis, Bluyé DeMessie, Caroline R desJardins-Park, Audrey H Effenberger, Felipe Flores, Michael Giles, Emma Y He, Nike S Izmaylov, ChangWon C Lee, Nicholas A Pagel, Krystal K Phu, Leah U Rosen, Danielle A Seda, Yong Shen, Santiago Vargas, Andrew W Murray, Eden Abebe, Sunia A Trauger, David A Donoso, Miguel Vences, Lauren A O'Connell
Publikováno v:
PLoS ONE, Vol 13, Iss 12, p e0207940 (2018)
Poison frogs acquire chemical defenses from the environment for protection against potential predators. These defensive chemicals are lipophilic alkaloids that are sequestered by poison frogs from dietary arthropods and stored in skin glands. Despite
Externí odkaz:
https://doaj.org/article/46b30a198fb3489293183c6da339fab1
Autor:
Ji-Sun Yoo, Byoungsook Goh, Kyoo Heo, Da-Jung Jung, Wen Zheng, ChangWon C. Lee, Naama Geva-Zatorsky, Meng Wu, Seung Bum Park, Dennis L. Kasper, Sungwhan F. Oh
Publikováno v:
bioRxiv
SummaryBioactive metabolites produced by symbiotic microbiota causally impact host health and disease, nonetheless, incomplete functional annotation of genes as well as complexities and dynamic nature of microbiota make understanding species-level co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7a8aae072451a24a5f61c84bdf68665
https://europepmc.org/articles/PMC10245877/
https://europepmc.org/articles/PMC10245877/
Autor:
Da-Jung Jung, Jérôme Le Nours, Dennis L. Kasper, Jesang Lee, ChangWon C. Lee, Hyun-Soo Kim, Seung Bum Park, Yoon Soo Hwang, Deniz Erturk-Hasdemir, Jamie Rossjohn, Ji-Sun Yoo, Heebum Song, T. Praveena, Sungwhan F. Oh, Richard S. Blumberg
Publikováno v:
Nature
Small molecules derived from symbiotic microbiota critically contribute to intestinal immune maturation and regulation1. However, little is known about the molecular mechanisms that control immune development in the host–microbiota environment. Her
Publikováno v:
Clinical Pharmacology & Therapeutics. 110:1050-1056
Launched in 2002, originator adalimumab (Humira) is the top revenue-generating drug in the United States. Between 2016 and 2019, the US Food and Drug Administration approved 5 adalimumab biosimilars, yet none have been marketed owing to patent disput
Publikováno v:
Value in Health. 24:804-811
In the United States, brand-name prescription drugs remain expensive until market exclusivity ends and lower-cost generics become available. Delayed generic drug uptake may increase spending and worsen medication adherence and patient outcomes. We as
Publikováno v:
JAMA Internal Medicine. 183:275
This cross-sectional study assesses Medicaid spending associated with citrate-free vs original adalimumab.
Autor:
Beatrice L. Brown, Mayookha Mitra-Majumdar, Osman Moneer, Jerry Avorn, ChangWon C. Lee, Aaron S. Kesselheim, Martin Kulldorff, Jonathan J. Darrow
Publikováno v:
Health Affairs. 40:25-32
The Food and Drug Administration generally approves vaccines when their benefits outweigh their risks for their intended use. In this paper, we review current and potential approaches to this criti...
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:367-371
Brand-name drugs have periods of market exclusivity before generic competition begins. Due to high brand-name drug prices charged during this period, market exclusivity is an important determinant of US prescription drug spending. We used claims data
Autor:
Thomas Rosemann, Thomas Grischott, Aaron S. Kesselheim, Paola Daniore, Thomas J Hwang, Kerstin Noëlle Vokinger, Ariadna Tibau, ChangWon C. Lee
Publikováno v:
JAMA Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
JAMA Oncol
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
JAMA Oncol
IMPORTANCE The high cost of cancer medicines is a public health challenge. Policy makers in the US and Europe are debating reforms to drug pricing that would cover both the prices of new medicines when entering the market and price increases after th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74b42dec71ef605caff4f6ea03331c40
https://doi.org/10.5167/uzh-206610
https://doi.org/10.5167/uzh-206610
Publikováno v:
J Gen Intern Med